Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Campaign trail issues and answers: Medicare reform, health law repeal still part of the mix

How is Medicare playing among the ever-important bloc of Florida senior citizens as the two presidential candidates vie for their votes? Similarly, it's also a hot topic in the Montana Senate race, which is one of the most intensely watched in the country.

1 Nov 2012

‘Off the shelf’ stem cells show promise for perianal fistula

Expanded allogenic adipose-derived stem cells are effective for the treatment of perianal fistula in patients with Crohn’s disease, suggest the results of a phase I/II trial.

31 Oct 2012

Romney's promise to repeal 'Obamacare' makes it into candidates' foreign policy debate

GOP challenger Mitt Romney said he would pay for military spending increases by repealing the 2010 health law and scaling back other health programs.

24 Oct 2012

Possible overlap exists between inflammatory bowel disease and IBS

Research unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas suggests a possible overlap of symptoms of two prevalent GI disorders: irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) and further suggests a possible link between subtle GI tract inflammation and IBS symptoms-a link that is also the focus of the first systemic review of the literature on this topic and an editorial both published in this month's American Journal of Gastroenterology.

23 Oct 2012

$Ustekinumab success in refractory Crohn’s disease$

Ustekinumab success in refractory Crohn’s disease

Patients with Crohn’s disease who have failed to respond adequately to anti–tumor necrosis factor treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind, placebo-controlled trial suggest.

22 Oct 2012

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San Diego, School of Medicine.

18 Oct 2012

Researchers identify IL-27 molecule involved in counterbalancing the immune system attack

We couldn't live without our immune systems, always tuned to detect and eradicate invading pathogens and particles. But sometimes the immune response goes overboard, triggering autoimmune diseases like lupus, asthma or inflammatory bowel disease.

29 Sep 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

Abbott receives FDA approval for Humira to treat ulcerative colitis

The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults.

29 Sep 2012

Hundreds of new genes are involved in function and development of T-cells

A research team led by investigators at New York University and NYU School of Medicine has determined how cells that cause inflammatory ailments, such as Crohn's disease, multiple sclerosis, and arthritis, differentiate from stem cells and ultimately affect the clinical outcome of these diseases.

27 Sep 2012

Study unlocks secrets in bone marrow that could lead to improved treatments for colitis, Crohn's

Michigan State University researchers have unlocked secrets in bone marrow that could lead to improved treatments for colitis and Crohn's disease.

25 Sep 2012

Endothelial colony-forming cells show promise against inflammatory bowel disease

New research shows that a special population of stem cells found in cord blood has the innate ability to migrate to the intestine and contribute to the cell population there, suggesting the cells' potential to treat inflammatory bowel disease (IBD).

20 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Friendly bacteria: do we really need to eat probiotic yogurts?

According to the World Health Organization (WHO) probiotics are “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.

19 Sep 2012

Loss of normal microbial diversity may be culprit behind chronic sinusitis

A common bacteria ever-present on the human skin and previously considered harmless, may, in fact, be the culprit behind chronic sinusitis, a painful, recurring swelling of the sinuses that strikes more than one in ten Americans each year, according to a study by scientists at the University of California, San Francisco.

13 Sep 2012

BRI scientists receive two major grant awards for research into autoimmunity prevention

Benaroya Research Institute at Virginia Mason (BRI) recently received two major grant awards to explore how to regulate the immune system, as part of a nationwide collaborative program to prevent autoimmune diseases.

11 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012

EC grants European market authorization for Revestive to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the European Commission has granted European market authorization for the medicinal product teduglutide (trade name in Europe: Revestive) as a once-daily treatment for adult patients with short bowel syndrome.

5 Sep 2012

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Soligenix, Inc., a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

31 Aug 2012

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Campaign trail issues and answers: Medicare reform, health law repeal still part of the mix

‘Off the shelf’ stem cells show promise for perianal fistula

Romney's promise to repeal 'Obamacare' makes it into candidates' foreign policy debate

Possible overlap exists between inflammatory bowel disease and IBS

Ustekinumab success in refractory Crohn’s disease

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Researchers identify IL-27 molecule involved in counterbalancing the immune system attack

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott receives FDA approval for Humira to treat ulcerative colitis

Hundreds of new genes are involved in function and development of T-cells

Study unlocks secrets in bone marrow that could lead to improved treatments for colitis, Crohn's

Endothelial colony-forming cells show promise against inflammatory bowel disease

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Friendly bacteria: do we really need to eat probiotic yogurts?

Loss of normal microbial diversity may be culprit behind chronic sinusitis

BRI scientists receive two major grant awards for research into autoimmunity prevention

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

EC grants European market authorization for Revestive to treat short bowel syndrome

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in